Author: Robin Feldman

Jaime King on Challenges to State Attempts at Controlling Prescription Drug Costs

Published on Author Robin Feldman

 Professor Jaime King’s article, “The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs,” coauthored with Katherine Gudiksen and published in Journal of Legal Medicine, is a clear and cogent piece that adds to her distinguished scholarship on some of the most complex challenges facing the U.S. healthcare system. In the process,… Continue reading Jaime King on Challenges to State Attempts at Controlling Prescription Drug Costs →

Jaime King on California’s Drug Transparency Law

Published on Author Robin Feldman

When Governor Jerry Brown signed California’s drug transparency law, Senate Bill 17 (SB-17), in 2017, the state took a crucial first step towards increased transparency and accountability in a landscape of skyrocketing prescription-drug prices. Not only does SB-17 require drug manufacturers and health insurers to disclose information about rising prescription-drug prices, but it also represents… Continue reading Jaime King on California’s Drug Transparency Law →

Jaime King on the Anti-Competitive Potential of Cross-Market Mergers in Health Care

Published on Author Robin Feldman

What drives health care costs ever higher? Consolidation may be playing a key role. In this context, Professor Jaime King’s contribution to the St. Louis University Annual Health Law Symposium, “The Anti-Competitive Potential of Cross-Market Mergers in Health Care” (coauthored with Erin C. Fuse Brown), is a clarion call for antitrust authorities to consider seriously… Continue reading Jaime King on the Anti-Competitive Potential of Cross-Market Mergers in Health Care →